Scientists at UC San Francisco have developed a powerful new cancer therapy that remains inactive until it reaches the brain, where it switches on to attack deadly tumors. The engineered immune cells, called B-SYNC CAR-T cells, completely eliminated diffuse midline glioma (DMG), an aggressive childhood brain cancer that is almost always fatal within a year, in two mouse models.
This story was curated by Byte Panorama from reporting published by All Top News -- ScienceDaily. Our summary condenses the essential facts available at the time of collection; it does not reproduce the full article. Details, quotes and later updates may appear in the original report.